Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models

Table 1

Expression of endocannabinoids in animal models of CINP.

CINP model			Expression of endocannabinoids		Reference
Chemotherapy drug	Animals	CINP symptom	Tissue	Change in endocannabinoid levels relative to control
Cisplatin	Male C3H/HeN mice	Mechanical and heat hyperalgesia	Plantar paw skin	Decrease in AEA but no change in 2-AG	[25]
Cisplatin	Male SD rats	Mechanical and cold allodynia	Lumbar spinal cord	Both 2-AG and AEA increased	[24]
			Dorsal hind paw skin	2-AG decreased but not AEA
Cisplatin	Male C3H/HeN mice	Mechanical hyperalgesia	Plantar paw skin	Both 2-AG and AEA decreased	[26]
			DRGs	Both 2-AG and AEA decreased
			Lumbar spinal cord	Both 2-AG and AEA increased
			Midbrain	No effect on both 2-AG and AEA
Cisplatin	Male C3H/HeJ mice	Mechanical allodynia	Plantar paw skin	Decrease in AEA but no change in 2-AG	[27]

2-AG, 2-arachidonoylglycerol; AEA, N-arachidonoylethanolamine (anandamide); SD, Sprague-Dawley.